Leanet Cabrera
Family · Cutler Bay, FLNPI 1811455637
Payments from drug & device makers
Across 69 payments — averaging $29.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$511
- Novo Nordisk$376
- Otsuka America Pharmaceutical, Inc.$234
- Revance Therapeutics, Inc.$175
- AstraZeneca$122
- Amarin Pharma, Inc.$108
- plus $537 from 16 others
What the payments were for
- Food & beverage$2,063100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 14 | $511 |
| Novo Nordisk | 10 | $376 |
| Otsuka America Pharmaceutical, Inc. | 7 | $234 |
| Revance Therapeutics, Inc. | 2 | $175 |
| AstraZeneca | 1 | $122 |
| Amarin Pharma, Inc. | 6 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $103 |
| AbbVie | 4 | $79 |
| Lilly USA, LLC | 5 | $72 |
| Esperion Therapeutics, Inc. | 3 | $47 |
| Novartis | 2 | $29 |
| Lundbeck LLC | 1 | $29 |
| Urovant Sciences Inc | 1 | $28 |
| Viiv Healthcare Company | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| KCI USA, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Radius Health, Inc. | 1 | $13 |
| GSK | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,063 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 16 | $19,712 |
| VelphoroSucroferric Oxyhydroxide | 11 | $18,726 |
| EliquisApixaban | 35 | $15,689 |
| Repatha SureclickEvolocumab | 11 | $6,940 |
| MyrbetriqMirabegron | 19 | $4,366 |
| ClopidogrelClopidogrel Bisulfate | 18 | $708 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $689 |
| Tamsulosin Hcl | 13 | $396 |
| Testosterone Cypionate | 12 | $369 |
| Losartan Potassium | 23 | $321 |
| Atorvastatin Calcium | 12 | $275 |
| Irbesartan | 12 | $220 |
| Amlodipine Besylate | 13 | $200 |
| Rosuvastatin Calcium | 11 | $177 |
| Dorzolamide Hcl | 12 | $147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $72 | $19,71216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.
Other family in Cutler Bay
- Raymel HernandezCutler Bay$103K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.